Investing.com -- Jefferies upgraded German solar inverter manufacturer SMA Solar to “buy” from “hold” and raised its price target to €39 from €22, citing improved profitability prospects driven by ...

In light of geopolitical tensions and real purchasing power losses, precious metal prices are on the rise – and there is no ...

A leading Shropshire electrical services company is celebrating its 10-year anniversary this month, marking a decade of ...

Using mainly German technology, German-based Photon Energy will install a 215 kWh solar PV powered battery system that will replace the current power system of a broadcast antenna near Muswellbrook in ...

There are many ways products can aid installation in the residential market, whether it’s software that makes designing easier or mounting systems with fewer parts to assemble. For the 2024 Top ...

SCHAUMBURG, Ill., Nov. 26, 2025 /PRNewswire/ -- Cure SMA, the leading nonprofit organization dedicated to supporting those impacted by spinal muscular atrophy (SMA), welcomes the FDA approval of ...

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function ...

The global solar inverter market was valued at US$12.81 billion in 2023 and is forecasted to reach US$24.40 billion by 2029, with a CAGR of 11.34% from 2024-2029. Solar inverters are crucial for ...

Onasemnogene abeparvovec-brve is the first gene replacement therapy approved for SMA patients aged 2 years and older, expanding access beyond infants. Phase 3 trials demonstrated significant motor ...

The approval is supported by findings from the open-label Phase IIIb STRENGTH study and the Phase III STEER study.

Itvisma, an intrathecal version of Zolgensma, can be used in children, teens and adults to stabilize or improve motor ...

Novartis is on the final straight to approval of its spinal muscular atrophy (SMA) gene therapy Zolgensma in the EU, after getting a recommendation for approval from the CHMP. The positive opinion ...